MedDataX Logo

Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)

NCT ID: NCT01284608

Last Updated: 2012-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

197 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-03-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Observational prospective metabolic changes metabolic syndrome diabetes prostatic cancer risk fracture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Prostate cancer patient requiring androgen-ablation treatment: LHRH analogs, surgical castration, antiandrogen treatment
* Provision of informed consent prior to conducting any study-related procedure

Exclusion Criteria

* Patient involved in a Clinical Trial
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Albacete, Albacete, Spain

Site Status

Research Site

El Ejido, Almeria, Spain

Site Status

Research Site

Huercal Overa, Almeria, Spain

Site Status

Research Site

Mérida, Badajoz, Spain

Site Status

Research Site

Palma de Mallorca, Balearic Islands, Spain

Site Status

Research Site

Barcelona, Barcelona, Spain

Site Status

Research Site

El Hospitalet de Llobregat, Barcelona, Spain

Site Status

Research Site

Sabadell, Barcelona, Spain

Site Status

Research Site

Aranda de Duero, Burgos, Spain

Site Status

Research Site

Miranda de Ebro, Burgos, Spain

Site Status

Research Site

Córdoba, Cordoba, Spain

Site Status

Research Site

Ferrol, Coru?a, Spain

Site Status

Research Site

Granada, Granada, Spain

Site Status

Research Site

Guadalajara, Guadalajara, Spain

Site Status

Research Site

Donostia / San Sebastian, Guipuzcoa, Spain

Site Status

Research Site

Jaén, Jaen, Spain

Site Status

Research Site

Logroño, La Rioja, Spain

Site Status

Research Site

Monforte (casco Urbano), Lugo, Spain

Site Status

Research Site

Alcalá de Henares, Madrid, Spain

Site Status

Research Site

Coslada, Madrid, Spain

Site Status

Research Site

Madrid, Madrid, Spain

Site Status

Research Site

Majadahonda, Madrid, Spain

Site Status

Research Site

San Sebastián de los Reyes, Madrid, Spain

Site Status

Research Site

Antequera, Malaga, Spain

Site Status

Research Site

Vigo, Pontevedra, Spain

Site Status

Research Site

Osuna, Sevilla, Spain

Site Status

Research Site

Reus, Tarragona, Spain

Site Status

Research Site

Toledo, Toledo, Spain

Site Status

Research Site

Barakaldo, Vizcaya, Spain

Site Status

Research Site

Bilbao, Vizcaya, Spain

Site Status

Research Site

Galdakao, Vizcaya, Spain

Site Status

Research Site

Calatayud, Zaragoza, Spain

Site Status

Research Site

Zaragoza, Zaragoza, Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-OES-DUM-2010/1

Identifier Type: -

Identifier Source: org_study_id